Tech

OpenEvidence Valued at $12B After $250M Funding Round

OpenEvidence closed a $250 million financing round led by Thrive Capital and DST Global, lifting its valuation to $12 billion. The claims come with caveats, including unverifiable data and anonymous sources, but the funding track signals strong demand for AI-enabled clinical decision support.

📅 January 21, 2026
⏱️ 2 min read
OpenEvidence Valued at $12B After $250M Funding Round

Key Takeaways

  • OpenEvidence’s post-money valuation reached $12 billion after a $250 million round led by Thrive Capital and DST Global.
  • Total funding to date is about $700 million, including a prior $75 million from Sequoia at a $1 billion valuation.
  • The latest round includes Google Ventures, Nvidia, Kleiner Perkins, Craft Ventures (David Sacks), and Mayo Clinic as investors.
  • Valuation milestones progressed from $1B (Feb 2025) to $6B (Oct 2025) to $12B (Jan 2026).
  • Claims of 40% physician adoption and $100M+ annual revenue are unverified, and the revenue model relies on advertising.

People Involved

  • Daniel NadlerCEO, OpenEvidence
  • David SacksPartner, Craft Ventures

Entities Involved

  • OpenEvidenceAI clinical decision support platform
  • Thrive CapitalLead investor in the round
  • DST GlobalLead investor in the round
  • SequoiaEarlier investor
  • Google VenturesInvestor
  • NvidiaInvestor
  • Kleiner PerkinsInvestor
  • Craft VenturesInvestor (David Sacks)
  • Mayo ClinicStrategic investor

MarketMoodz Analysis

For investors, the round underscores strong appetite for AI-enabled clinical decision support and the potential for rapid scale in an ad-supported model that aims to monetize usage across small practices. The path to profitability will hinge on achieving scale, managing data-privacy and regulatory hurdles, and defeating competition from HIPAA-compliant health AI offerings.

The valuation trajectory — $1B in Feb 2025, $6B in Oct 2025, and $12B in Jan 2026 — mirrors a broader surge in professional AI tools, but the story is still contingent on independent revenue visibility and long‑term sustainability of an ad‑based approach within healthcare.

What to watch next: audited revenue or third-party disclosures, regulatory updates on data handling, progress in HIPAA compliance, and any signs of profitability or unit economics as adoption expands across physician practices.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial